GRAIL (Galleri)

What is GRAIL (Galleri)?

GRAIL (Galleri) is a company within the Biotechnology category. GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. It developed the Galleri test, a multi-cancer early detection blood test that can detect a signal shared by more than 50 types of cancer with a low false positive rate.

When was GRAIL (Galleri) founded and where is it based?

GRAIL (Galleri) was founded in 2016 and is headquartered in Menlo Park, CA.

What is GRAIL (Galleri)'s Brand Authority Index tier?

GRAIL (Galleri) is rated Contender on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.

How accurately do AI models describe GRAIL (Galleri)?

AI narrative accuracy for GRAIL (Galleri) is Moderate. Significant factual deltas detected. Inconsistent representation across models.

How do AI models position GRAIL (Galleri) competitively?

AI models classify GRAIL (Galleri) as a Challenger. AI names competitors first.

How visible is GRAIL (Galleri) in buyer-intent AI queries?

GRAIL (Galleri) appeared in 6 of 8 sampled buyer-intent queries (75%). GRAIL dominates 'multi-cancer early detection' queries but loses visibility on broader 'liquid biopsy' searches to established diagnostic giants.

What do AI models currently say about GRAIL (Galleri)?

AI identifies this brand as a pioneer in liquid biopsy for multi-cancer detection with high scientific authority. However, it often struggles to provide current details on the 2024 spin-off from Illumina and the specific insurance coverage landscape. Key gap: The most significant gap is the real-time availability and insurance coverage status, which frequently changes and is often described as 'widely available' when it remains largely a self-pay or employer-sponsored benefit.

How many facts about GRAIL (Galleri) are well-documented vs need fixing vs retrieval-dependent?

Of 5 key facts verified about GRAIL (Galleri), 3 are well-documented (likely accurate across AI models), 2 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.

What is GRAIL (Galleri)'s biggest AI narrative vulnerability?

Misinterpretation of FDA approval status (Full Approval vs. LDT status) which impacts perceived medical legitimacy.

What does GRAIL (Galleri) offer?

GRAIL (Galleri)'s core products are Galleri (Multi-Cancer Early Detection Test).

How is GRAIL (Galleri) priced?

GRAIL (Galleri) uses Enterprise/Custom (Employer plans) or Custom (approx. $949 self-pay).

Who does GRAIL (Galleri) target?

GRAIL (Galleri) serves Healthcare systems, self-insured employers, and individuals age 50+ at elevated risk for cancer..

What differentiates GRAIL (Galleri) from competitors?

GRAIL (Galleri) The ability to detect 50+ cancers from a single blood draw using proprietary methylation-based cfDNA technology with a <1% false positive rate.

Verified from GRAIL (Galleri) website

Founded: 2016

Headquarters: Menlo Park, California, USA